|
|
Global Endocrine Pharmaceutical MarketPublished by: Visiongain Published: Mar. 1, 2005 Table of ContentsChapter 1: Executive Summary 1.1 Report Parameters 1.2 The Endocrine System and Disease 1.3 The Endocrine Glands of the Body 1.4 The Hypothalamus and the Anterior Pituitary 1.5 The Hypothalamus and the Posterior Pituitary 1.6 The Endocrine System 1.7 The Effects of Hormones 1.8 Types of Hormones 1.9 Mechanism of Action 1.10 Control of Hormone Secretion 1.11 Negative Feedback 1.12 Positive Feedback 1.13 Diseases of the Endocrine System Chapter 2: The Global Endocrine Disease Market 2.1 2005 Global Endocrine Market Valued at $19.9bn 2.2 Endocrine Disease Winners & Losers 2.3 Endocrine Market Drivers 2.4 Endocrine Market Restraints 2.5 Hypertension 2.6 Osteoporosis 2.7 Diabetes 2.8 Growth Hormone Replacement 2.9 Infertility 2.10 Acromegaly 2.11 Hypothyroidism 2.12 Endocrine Market by Worldwide Region Chapter 3 The Global Pituitary Disease Market 3.1 The Posterior Pituitary 3.2 Undersecetion of Vasopressin 3.3 The Anterior Pituitary 3.4 Oversecretion of Pituitray Hormones 3.5 Undersecretion of Pituitary Hormones 3.6 Growth Hormone (GH) 3.7 Effects of GH Secreting Tumours 3.8 Hyposecretion of Growth Hormone 3.8 Prolactin 3.9 The World Market for Pituitary Disease Pharmaceuticals 3.10 Sandostatin and Trovert Go Head-to Head 3.11 Acromegaly Market Share: The Fall of Sandostatin 3.12 Acromegaly Market Set to Become a Blockbuster 3.13 Acromegaly Drivers 3.14 Acromegaly Restraints 3.15 Acromegaly Pipeline, 2005 3.16 Genotropin Leads the GH Replacement Market Despite all in Sales 3.17 Novo Nordisk's Products Drive GH Replacement Market 3.18 GH Replacement Drugs Revenues Forecast to Grow Well 3.19 GH Replacement Market Drivers 3.20 GH Replacement Market Restraints 3.21GH Replacement Pipeline Portfolio, 2005 Chapter 4: The Global Hypertensive Market 4.1 Introduction to Hypertension 4.2 Compensatory Mechanisms for Regulating Blood Pressure 4.3 The Renin-Angiotensin System 4.4 Regulation of the Renin-Angiotensin II System 4.5 The Clinical Treatment of Hypertension 4.6 Calcium Channel Blockers 4.7 Angiotensin II Receptor Blockers (ARBs) 4.8 Diuretics 4.9 Beta-Blockers 4.10 Angiotensin-Converting Enzyme (ACE) Inhibitors 4.11 Antihypertensive Therapy with ACE Inhibitors 4.12 Combined Antihypertensive Treatments 4.13 Enalapril (Vasotec) 4.14 The Market for Anti-Hypertensive Drugs 4.15 Pfizer Reigns the Hypertensive Market 4.16 ARB's Are the Highest Earners 4.17 Diovan and Co-Diovan: Fastest Growing Hypertensives 4.18 Cozaar and Hyzaar: World Class Hypertensives from Merck 4.19 ARB Future Looks Good 4.20 Will Norvasc Continue to Dominate the Antihypertensive Market? 4.21 The World Market for Angiotensin II Enzyme Inhibitors and Antagonists 4.22 Total Global Endocrine Hypertensive Market Expected to Clear $3.5bn 4.23 Total Global ARB Market Has High Expectations 4.24 ACE Market Will Lose Out to ARBs 4.25 Drivers of Hypertensive Market 4.26 Restraints of Hypertensive Markets 4.27 Hypertensive Pipeline Portfolio, 2005 Chapter 5: The Global Diabetes Market 5.1 Introduction to Diabetes 5.2 The Biology of Diabetes Mellitus 5.3 Diabetes Mellitus Type 1 5.4 Diabetes Mellitus Type 2 5.5 Gestational Diabetes 5.6 Maturity- Onset Diabetes in Youth 5.7 Secondary Diabetes 5.8 The Pharmaceutical Treatment of Diabetes 5.8.1 Insulin Analogues 5.8.2 Insulin Sensitising Drugs 5.8.3 Alpha-Glucosidase Inhibitors 5.8.4 Sulfonylureas 5.8.5 Repaglinide 5.9 Two Diabetes Blockbusters Gained in 2003 5.10 Thiazolidinediones: The Leading Diabetic Therapeutics, 2003 5.11 Diabetes Company Winners and Losers 5.12 The Saturated Insulin Market of 2003 5.13 Do Any Currently Marketed Diabetes Drugs Have Blockbuster Potential? 5.14 Novo Nordisk Claims New Product Superior to Lantus 5.15 Aventis's Apidra Similar to Humulog 5.16 Innovative Insulin Delivery Technology: The Race is Hotting Up! 5.17 Implantable Insulin Pumps 5.18 Insulin Pills 5.19 Transdermal Insulin 5.20 Oral Spray Insulin00-2005 5.21 Inhaled Insulin 5.22 Numerous Potential Blockbusting Diabetes Products Set to Arrive 2005-2007 5.23 Exubera: The Wait Continues 5.24 Oralin: Liquid Aerosol Insulin 5.25 Hexyl-Insulin Monoconjugate (HIM2) 'Nowhere Near Phase III' 5.26 AERx iDMS Earlier Market Launch Expected 5.27 Diabetes Market Set to Soar to $19bn by 2010 5.28 Diabetes Market Drivers 5.29 Diabetes Pipeline is Busy Chapter 6: The Global Infertility Market 6.1 Introduction to Infertility 6.2 Rises in Infertility 6.3 Causes of Infertility 6.4 The Endocrine Control of Fertility 6.5 The Female Reproductive System 6.6 The Male Reproductive System 6.7 Feedback Control 6.8 Assisted Reproductive Technologies (ART) 6.9 The Pharmacological Control of Infertility 6.9.1 Clomiphene Citrate 6.9.2 Gonadotrophins (LH/FSH) 6.9.3 GnRH Antagonists 6.9.4 Bromocriptene 6.10 The World Market for the Pharmacological Treatment for Infertility 6.11 Gondatrophins Rule the Infertility Market 6.12 Serono Domainates Infertility Drug Market 6.13 Serono's Luveris: A Reveloutionary New Product 6.14 Infertility Drug Market Potential Value Clears $1.5bn 7. Global Osteoporosis Market 7.1 Introduction to Osteoporosis 7.2 The Importance of Oestrogen 7.3 The Endocrine Control of Bone Metabolism 7.4 Overview to the Pharmaceutical Treatment of Osteoporosis 7.5 Bisphosphonates 7.6 Estrogen and Hormone Replacement Therapy 7.7 Selective Estrogen Receptor Modulator (SERM) 7.8 Calcitonin 7.9 Vitamin D and Calcium Supplements 7.10 Forteo: The Miracle Cure of Osteoporosis? 7.11 The 3 Major Changes of the Osteoporosis Pharmaceutical Market 7.12 The World Market for the Pharmaceutical Treatment for Osteoporosis Lead by Fosamax 7.13 Bisphosphonates: The Leading Class of Osteoportic Drugs, 2003 7.14 Merck: The Leading Osteoporosis Company, 2003 7.15 Osteoporosis Global Market is Worth $7.6bn in 2005 7.16 PTH/Anabolic Agents Will Dominate the 2010 Osteoporosis Market 7.17 SERMs Also Expected to Perform Well 7.18 Bisphosphonates Will Suffer Due To Fosamax's Patency-Expiry 7.19 Osteoporosis Market Drivers 7.20 Osteoporosis Market Restraints 7.21 The Women's Health Institute HRT Study 7.22 Osteoporosis Future Developments 8. Global Thyroid Disease Market 8.1 Introduction to the Thyroid Gland 8.2 The Regulation and Function of T3/T4 Secretion 8.3 Hypothyroidism 8.4 Hyperthyroidism 8.5 The Treatments for Hyperthyroidism 8.6 The Pharmaceutical Control of Hyperthyroidism 8.6.1 Tapazole 8.6.2 Propylthiuoracil 8.7 The Rule of Synthroid 8.8 Levoxyl Product Recall Chokes Kings Revenues 8.9 The Generics Are Coming! Low-Cost Versions of Synthroid and Levoxyl are Approved 8.10 Hypothyrodism Revenues Set to Hypo! 8.11 Drivers of the Hypotension Market 8.12 Restraints of the Hypotension Market 8.13 The World Market for the Treatment of Hyperthyroidism 8.14 Drivers of the Hyperthyroidism Market 8.15 Restraints of the Hyperthyroidism Market 9. Global Adrenal Disease Market 9.1 Introduction to Adrenal Glands 9.2 Adrenocortical Control 9.3 The Functions of Cortisol 9.4 The Functions of Aldosterone 9.5 Addison's Disease 9.6 Medrol 9.7 Florinef 9.8 Cushing's Syndrome 9.9 Drug-related Adrenal Insufficiency 9.10 Hyperaldosteronism (Conn's Syndrome) 9.11 Aldactone 9.12 Midamor 9.13 World Market for Adrenocortical Pharmaceuticals 9.14 The World Market for Medrol is Put On-Hold! Tables Table 1.1: The Global Endocrine Diseases Market, 2003-2010 Table 1.2: The Endocrine System Table 1.3: Endocrine Diseases Table 2.1: Global Forecast Revenues ($m) for the Endocrine Disease Market, 2003-2010 Table 2.2: Changes in Market Share (%) Between 2003 and 2010 of the Major Endocrine Disease Markets Table 2.3: Global Revenues ($m) 2003 and 2010 for all Endocrine Diseases Table 2.4: Global Revenues ($m) and Growth Rates (%) for the Pharmaceutical Treatment of Endocrine Disease, 2004 Table 2.5: Global Revenues, 2003 and 2010, for the Main Pharmaceutical Treatment Areas of Endocrine Disease Table 2.6: Global Revenue ($m) by Country Region, 2004 Table 3.1: The Hormones Secreted by the Anterior Pituitary Table 3.2: Global Revenues ($m) for Sandostatin, 2002 and 2003 Table 3.3: The 2003 Global Acromegaly Market: Revenues and Market Share by Drug Table 3.4: The 2010 Global Acromegaly Market: Revenues and Market Share by Drug Table 3.5: World Acromegaly Market Revenue Forecast by Drug, 2003-2010 Table 3.6: Acromegaly Pipeline Portfolio, 2005 Table 3.7: Global Market Revenues ($m) for GH Replacement Drugs, 2002 & 2003 Table 3.8: Global GH Replacement Drugs Market Share, 2002 & 2003 Table 3.9: Global Forecast Revenues ($m) and Growth Rates (%) for GH Replacement Drugs, 2003-2010 Table 3.10: Growth Hormone Replacement Drug Pipeline Portfolio, 2005 Table 4.1: The Global Market for Hypertension Drugs, 2003 Table 4.2, The Global Market for Hypertensive Drugs by Company, 2003 Table 4.3, Global Market Share for Hypertensive Drugs, 2003 Table 4.4: Endocrine Controlled Hypertensives Market, 2003 Table 4.5: Total Endocrine Hypertensive Drug Market Forecast ($m) by Class, 2003-2010 Table 4.6: Hypertensive Pipeline Products in Late Developmental Stages, 2005 Table 5.1: Global Market ($m) and Growth Rates for Diabetes Drugs, 2003 Table 5.2: The Global Market ($m) for Diabetic Drugs by Class, 2002 & 2003 Table 5.3: The Global Market ($m) for Diabetic Drugs by Company, 2002 & 2003 Table 5.4: Oral and Human Insulin Diabetes Drugs Market Share (%), 2002 & 2003 Table 5.5: 2005-2007 Pipeline Diabetes Drugs with Blockbuster Potential Table 5.6: Total Global Diabetes Market Revenue (Sm) Forecast for Insulins & Oral AntiDiabetic Drugs, 2003-2010 Table 5.7: Late-Stage Development Diabetes Pipeline Product Portfoilo, 2005 Table 6.1: Global Infertility Drug Market ($m) and Growth Rate (%), 2002 & 2003 Table 6.2: Serono's Infertility Drug Portfolio Performance, 2003 and 2004 Table 6.3: Total Global Infertility Drug Market Revenue ($m), 2002 & 2003 Table 6.4: Global Market Share (%) by Fertility Drug Class, 2002 & 2003 Table 6.5: Global Market Share (%) by Company, 2003 Table 6.6: Total Global Infertility Drug Market Revenue Forecast ($m), 2003-2010 Table 6.7: Global Infertility Drug Market Revenue Forecast ($m), 2003-2010 by Class Table 6.8: Infertility Pharmaceutical Pipeline Portfolio, 2005 Table 7.1: Global Market ($m) and Growth Rates for Osteoporoitic Drugs, 2003 Table 7.2: The Global Market ($m) for Osteoporosis Drugs by Drug Type, 2002 & 2003 Table 7.3: Osteoporosis Company Market Share by Revenue ($m), 2002 & 2003 Table 7.4: Total Global Osteoporosis Drug Market Revenue Forecast ($m), 2003-2010 Table 7.5: Total Global Osteoporosis Market Revenue ($m) By Drug Class, 2003-2010 Table 7.6: Osteoporosis Pipeline Product Portfolio, 2005 Table 8.1: Hypothyrodism Drug Products Available, 2005 Table 8.2: Hypothyrodism Market Revenues ($m), 2002 & 2003 by Drug Table 8.3: Hypothyrodism Market Share (%) 2002 & 2003 by Drug Table 8.4: Global Forecast for Revenue ($m) Growth of the Hypothyroid Market, 2003-2010 Table 8.5: Global Revenues (£$m) for the Hyperhyroid Market, 2004 Table 9.1 Indications of Medrol, 2005 Table 9.2: Adrenocortical Pharmaceuticals, 2005 Graphs Graph 1.1: Total Global Endocrine Market Revenues ($bn), 2003-2010 Graph 1.2: Total Global Endocrine Market Growth (%), 2004-2010 Graph 2.1: Total Endocrine Pharmaceutical Market Revenue ($m) Forecast by Diease, 2003-2010 Graph 2.2 Endocrine Therapeutic Area Revenues ($m), 2003 & 2010 Graph 3.1: Total Acromegaly Market Revenue ($m) Forecast 2003-2010 by Drug Graph 3.2: Total Acromegaly Market Revenue ($m) Forecast 2003-2010 Graph 3.3: Total Acromegaly Market Revenue Change (%) Forecast 2003- 2010 Graph 3.4: Total World GH Replacement Drug Market Revenue Forecast ($m), 2003-2010 Graph 3.5: Total World GH Replacement Drug Market Revenue Change Forecast (%), 2003-2010 Graph 4.1: World Endocrine Hypertensive Drug Market Revenue ($m) by Class, 2003-2010 Graph 4.2: Total World Endocrine Hypertensive Drug Market Revenue ($m), 2003-2010 Graph 4.3: Total World Endocrine Hypertensive Drug Market Revenue Growth (%), 2004-2010 Graph 5.1: Total Global Diabetes Market Revenue (Sbn) Forecast, 2003- 2010 Graph 5.2: Total Global Diabetes Market Growth (%) Forecast, 2003-2010 Graph 5.3: Total Global Diabetes Market Revenue Forecast ($m), for Insulins and Oral Anti-Diabetes Drugs, 2003-2010 Graph 6.1: Total Global Infertility Drug Market Revenue Forecast ($m), 2003-2010 Graph 6.2: Total Global Infertility Drug Market Growth Forecast (%), 2003-2010 Graph 6.3: Global Infertility Drug Market Revenue Forecast ($m), 2003-2010 by Class Graph 7.1: Total Global Osteoporosis Market Revenue ($m), 2003-2010 Graph 7.2: Total Global Osteoporosis Market Revenue Growth (%), 2003-2010 Graph 7.3: Total Global Osteoporosis Market Revenue ($m) By Drug Class, 2003-2010 Graph 8.1: Total Global Hypotension Market Revenue ($m), 2003-2010 Graph 8.2: Total Global Hypotension Market Revenue Loss (%), 2003-2010 Charts Chart 2.1: Total Global Endocrine Market Share (%) by Disease, 2003 Chart 2.2: Total Global Endocrine Market Share (%) by Disease, 2010 Chart 2.3: Global Endocrine Market Share (%) by Country Region, 2004 Chart 3.1: Acromegaly Market Share %, 2003 Chart 3.2: Acromegaly Market Share %, 2010 Chart 3.3: GH Replacement Drugs Market Share (%), 2002 Chart 3.4: GH Replacement Drugs Market Share (%), 2003 Chart 4.1: Hypertensive Market Share by Company, 2003 Chart 4.2: Hypertensive Market Share by Drug Class, 2003 Chart 5.1: Diabetes Market Share by Drug Class, 2002 Chart 5.2: Diabetes Market Share by Drug Class, 2003 Chart 5.3: Diabetes Market Share by Company, 2002 Chart 6.1: Global Fertility Drug Market Share (%) by Drug Class, 2002 Chart 6.2: Global Fertility Drug Market Share (%) by Drug Class, 2003 Chart 6.3: Global Fertility Drug Market Share (%) by Company, Chart 6.4: Global Infertility Drug Market Share (%) by Class, 2010 Chart 7.1: Total Osteoporotic Market Share (%) by Drug Class, 2002 Chart 7.2: Total Osteoporotic Market Share (%) by Drug Class, 2003 Chart 7.3: Total Osteoporotic Company Market Share (%), 2002 Chart 7.4: Total Osteoporotic Company Market Share (%), 2003 Chart 8.1: Hypothyrodism Market Share %, 2002 Chart 8.2: Hypothyrodism Market Share %, 2003 AbstractToday, the global endocrine pharmaceutical market is a highly lucrative multi-billion dollar business, but, can you confidently answer the following?
Visiongain values the total global endocrine market at $43.2bn in 2005, a growth of 13.5% from 2004. The endocrine diseases market is expected to grow over 100% over the forecast period, to produce revenues in 2010 of just under $70bn. Major changes of the market are expected over the forecast period, such as the arrival of insulin delivery technologies and massive losses of the hypothyroidism market due to increasing generic competition. Designed as an essential business aid, Endocrine 2005 provides a thorough evaluation of the market for you to keep ahead of your competitors. Learn about the four therapeutic area major earners of the industry:
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||